Allogene Therapeutics, a clinical-stage biotech developing allogeneic CAR T therapies for cancer, known as AlloCAR T, in collaboration with its development partner Servier, said that the U.S. Food & Drug Administration (FDA) has cleared Allogene’s Investigational New Drug (IND) application for ALLO-501 in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). Allogene is the sponsor of the ALLO-501 program.     The Phase 1 portion of the study is designed to assess the safety and to...